Compare A & BDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | A | BDX |
|---|---|---|
| Founded | 1999 | 1897 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medical/Dental Instruments |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.8B | 40.3B |
| IPO Year | 1999 | 1997 |
| Metric | A | BDX |
|---|---|---|
| Price | $130.56 | $145.52 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 13 |
| Target Price | $161.47 | ★ $186.00 |
| AVG Volume (30 Days) | ★ 2.4M | 2.3M |
| Earning Date | 05-27-2026 | 05-07-2026 |
| Dividend Yield | 0.92% | ★ 2.89% |
| EPS Growth | ★ 3.16 | N/A |
| EPS | ★ 2.27 | 0.25 |
| Revenue | $4,472,000,000.00 | ★ $21,840,000,000.00 |
| Revenue This Year | $8.45 | N/A |
| Revenue Next Year | $6.13 | $3.02 |
| P/E Ratio | ★ $57.19 | $584.96 |
| Revenue Growth | 6.43 | ★ 8.24 |
| 52 Week Low | $108.35 | $141.82 |
| 52 Week High | $160.27 | $213.08 |
| Indicator | A | BDX |
|---|---|---|
| Relative Strength Index (RSI) | 57.01 | 45.41 |
| Support Level | $121.63 | $142.48 |
| Resistance Level | $140.68 | $153.09 |
| Average True Range (ATR) | 4.17 | 3.20 |
| MACD | -0.39 | 0.16 |
| Stochastic Oscillator | 58.53 | 29.97 |
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life science and diagnostic firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools, cross lab consisting of consumables and services related to life science and applied tools, and diagnostics and genomics. Over half of its sales are generated from the biopharmaceutical, chemical, and advanced materials end markets, which we view as the stickiest end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the US and China representing the largest country concentrations.
Becton Dickinson operates in four business units. Medical essentials (35% of total sales) includes the legacy medical surgical unit, which sells catheters, syringes, and infection prevention products. Connected care (24%) core products include the Alaris infusion pump, Pyxis dispensing system, and pharmacy automation platforms. Biopharma systems (13%) produces prefillable syringes and autoinjectors. Interventional (29%) is composed of the surgery, peripheral vascular, and urology segments. More than 60% of revenue comes from the United States.